Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated DiseasesNew Program is a ...
Health on MSN3mon
Everything You Need To Know about IgA Nephropathy (IgAN)
Immunoglobin A nephropathy (also known as IgAN or Berger's disease) is a rare kidney disease that occurs when your immune ...
FierceBiotech3d
Climb Bio ascends from Eliem legacy with $9M upfront deal for preclinical IgA antibody
Eliem Therapeutics is continuing its transformation into an immune-mediated disease company by paying $9 million to ...
Morningstar3d
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
Climb Bio believes CLYM116 is a potential best-in-class approach to address significant unmet need in patients with IgA nephropathy and other B-cell mediated diseases. This transaction furthers ...